Ironwood Pharmaceuticals, Inc.

NasdaqGS:IRWD Stock Report

Market Cap: US$1.3b

Ironwood Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Ironwood Pharmaceuticals's earnings have been declining at an average annual rate of -25.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 2.5% per year.

Key information

-25.9%

Earnings growth rate

-26.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate2.5%
Return on equityn/a
Net Margin-226.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19
Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25
Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18
An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Ironwood Pharmaceuticals: Undervalued Company With Steady Growth

Sep 27

Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Jul 21
Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Jun 22
Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Ironwood Pharmaceuticals names Thomas McCourt permanent CEO

Jun 07

Revenue & Expenses Breakdown
Beta

How Ironwood Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:IRWD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23443-1,0021580
30 Sep 23432-9521240
30 Jun 23427-9171200
31 Mar 234171821180
31 Dec 224111751160
30 Sep 224211681160
30 Jun 224161731150
31 Mar 224225271120
31 Dec 214145281110
30 Sep 214135301160
30 Jun 214135091230
31 Mar 213981431310
31 Dec 203901061400
30 Sep 203991111440
30 Jun 20427971500
31 Mar 20440841580
31 Dec 19428591700
30 Sep 19433191800
30 Jun 19367-1531890
31 Mar 19346-1732070
31 Dec 18347-1942170
30 Sep 18310-1902270
30 Jun 18331-712380
31 Mar 18315-1082370
31 Dec 17298-552300
30 Sep 17292-1432290
30 Jun 17271-1432120
31 Mar 17260-1211910
31 Dec 16274-821730
30 Sep 16240-821500
30 Jun 16213-961350
31 Mar 16187-1231310
31 Dec 15150-1431250
30 Sep 15134-1661240
30 Jun 15112-1611220
31 Mar 1591-1731190
31 Dec 1476-1901170
30 Sep 1443-2041150
30 Jun 1431-2241170
31 Mar 1434-2291190
31 Dec 1323-2731230
30 Sep 1345-2651280
30 Jun 13136-1551200

Quality Earnings: IRWD is currently unprofitable.

Growing Profit Margin: IRWD is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IRWD is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.

Accelerating Growth: Unable to compare IRWD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IRWD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: IRWD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.